Tricuspid Valve Insufficiency

12

Review clinical trials related to Tricuspid Valve Insufficiency. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

EFS of the DUO System for Tricuspid Regurgitation

The study is an early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function of the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System).

Participants needed: 15
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: CroiValve LimitedUpdated: Jun 1, 2026Locations: 15
Eligibility criteria

Presence of severe or greater tricuspid regurgitation as determined by the Echo... [+5]

Patient is currently participating in another clinical investigation that could... [+30]

Status: Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team

Participants needed: 1,270
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Edwards LifesciencesUpdated: May 29, 2026Locations: 79
Eligibility criteria

Eighteen (18) years of age or older [+5]

Tricuspid valve anatomy not evaluable by TTE or TEE [+27]

Status: Not yet recruiting

Pivotal Trial to Evaluate the Safety and Effectiveness of the P&F TricValve® Transcatheter Bicaval Valve System

Pivotal trial to evaluate the safety and effectiveness of the P\&F TricValve® Transcatheter Bicaval Valve System.

Participants needed: 780
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: P+F Products + Features USA Inc.Updated: May 22, 2026Locations: 35
Eligibility criteria

Age between 18 years and 85 years old, at the time of signing the informed conse... [+7]

Patient had a recent MI, stroke, or cardiovascular accident; underwent coronary... [+35]

Status: Not yet recruiting

VDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)

Pivotal trial to evaluate the safety and clinical efficacy of the VDyne System for the treatment of symptomatic severe or greater tricuspid regurgitation.

Participants needed: 730
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: VDyne, Inc.Updated: Apr 8, 2026
Eligibility criteria

Age ≥18 years old [+7]

Subject unable or unwilling to comply with study required testing and follow-up... [+17]

Status: Recruiting

Evaluation of the Impact of Interventional Treatments for Symptomatic, Severe Tricuspid Valve Insufficiency on Renal Integrity and Function, as Well as on Physical Function and Activity in Older Adults.

The hypothesis is that renal function will improve following tricuspid valve intervention. A reduction in renal biomarkers is also expected. Furthermore, based on previous assessments, it is anticipated that there will be an improvement in volume status (reduced edema), symptom burden, and physical capacity in patients. Additionally, the study will assess the impact of the intervention on functional parameters such as motor capacity, physical activity, performance of activities of daily living, and ultimately, participation and quality of life.

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Robert Bosch Medical CenterUpdated: Mar 11, 2026Locations: 1
Eligibility criteria

Severe symptomatic tricuspid valve insufficiency and referral for TriClip/TricVa... [+3]

Dialysis-dependent/terminal kidney disease [+4]

Status: Recruiting

CorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study

The goal of this pivotal study is to demonstrate the safety and performance of the Cor TRICUSPID ECM (extracellular matrix) Valve (or Cor PEDIATRIC Tricuspid ECM Valve) for the surgical management of tricuspid valve disease and dysfunction in adult and pediatric patients. The main question(s) it aims to answer are: * whether the device may be implanted successfully and safely, and * whether the device effectively treats tricuspid valve disease and dysfunction through 12 months Participants will undergo: * preoperative evaluation * tricuspid valve replacement with the Cor TRICUSPID ECM Valve * postoperative evaluation, including at hospital discharge, 30 days, 6 months, and 12 months, and then annually thereafter through 5 years

Participants needed: 92
Trial details
Biological sex: AllType: InterventionalSponsor: Corvivo Cardiovascular, Inc.Updated: Sep 2, 2025Locations: 2
Eligibility criteria

Patient with a regurgitant or absent tricuspid valve requiring surgical treatmen... [+3]

Tricuspid annulus too small (< 10mm) to accommodate the Cor TRICUSPID ECM Valve [+17]

Status: Not yet recruiting

Korea VHD Echo Study: Surveillance of Aortic, Mitral & Tricuspid Patients - Insights From Real-world Practice

Valvular heart disease (VHD) is a growing public health concern globally, with increasing disease burden and rising interest in advanced treatment strategies such as transcatheter interventions. However, there remains a significant lack of real-world data regarding echocardiography practices, disease prevalence and progression, referral patterns, and treatment pathways. Addressing these gaps is critical for improving patient care and informing clinical decision-making. South Korea provides a unique opportunity to conduct a nationwide retrospective echocardiographic study due to its advanced healthcare infrastructure, high patient volume, and strong tradition in clinical research. The current study aims to evaluate the real-world burden and clinical journey of patients with moderate or severe valvular disease over a 10-year period, based on echocardiographic and electronic medical record (EMR) data collected from multiple tertiary centers across the country.

Participants needed: 30,000
Trial details
Age: 19+Biological sex: AllType: ObservationalSponsor: Yonsei UniversityUpdated: Jul 16, 2025Locations: 1
Eligibility criteria

Period: 2010.1.1~2020.12.31 [+3]

Poor image of echocardiography [+1]

Status: Recruiting

European Association of Cardiovascular Imaging Multiple and Mixed Valvular Disease Study

This study aims to investigate the prevalence and characteristics of multiple and mixed valvular heart disease (MMVD), which includes combinations of stenotic or regurgitant lesions on cardiac valves. The research will be conducted as a multicenter observational study, involving several centers worldwide, and will have a one-year follow-up period (with a possible extension to 5 years). The primary aim is to determine the proportion of MMVD among patients evaluated for valvular heart disease. Secondary aims include the evaluation of the epidemiologic distribution of clinical, biological, and cardiovascular imaging characteristics at baseline, management strategies, and their impact on prognosis. The study will also evaluate clinical outcomes such as mortality, hospitalization for heart failure, and changes in echocardiographic parameters. This research aims to provide valuable insights into the diagnosis, management, and prognosis of MMVD, addressing an important knowledge gap in this area.

Participants needed: 1,500
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Assistance Publique - Hôpitaux de ParisUpdated: Jun 3, 2024Locations: 1
Eligibility criteria

Age ≥ 18 years [+4]

History of prior valve surgery or percutaneous valve intervention (concerning a... [+2]

Status: Recruiting

Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®

Retrospective prospective Multicentric clinical follow up of patients with severe tricuspid regurgitation after being treated with the TricValve® Transcatheter Bicaval Valves System.

Participants needed: 450
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: P+F Products + Features GmbHUpdated: Apr 3, 2024Locations: 28Duration: 5 Years
Eligibility criteria

Successful treatment with TricValve Transcatheter Bicaval Valves System [+1]

no exclusion criterion

Status: Recruiting

Transcatheter Interventions for Tricuspid Insufficiency in Italy

This is an observational, multi-center, retrospective and prospective study collecting data about patients undergoing transcatheter tricuspid valve interventions in a real world clinical environment. The aim is to report clinical characteristics, procedural results and short- and long-term outcomes of patients undergoing transcatheter tricuspid valve interventions in Italian centres.

Participants needed: 200
Trial details
Age: 18-100Biological sex: AllType: ObservationalSponsor: Marianna AdamoUpdated: Feb 2, 2021Locations: 1Duration: 5 Years
Eligibility criteria

Patients undergoing transcatheter treatment of tricuspid regurgitation (native v... [+1]

Valve anatomy unsuitable for transcatheter tricuspid valve interventions. [+1]

Status: Recruiting

German Registry for Transcatheter Tricuspid Valve Interventions

Multicentre observational study of patients with severe tricuspid regurgitation and interventional treatment.

Participants needed: 600
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: LMU KlinikumUpdated: Dec 4, 2020Locations: 1Duration: 5 Years
Eligibility criteria

Interventional treatment of severe tricuspid regurgitation (isolated or in combi... [+1]

No agreement to participation [+1]

Status: Recruiting

THE TRAVEL TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve

The trial aims to evaluate the safety and effectiveness of LuX-Valve transcatheter tricuspid valve and delivery system which are intended to use in symptomatic patients with severe tricuspid regurgitation and high surgical risk.

Participants needed: 150
Trial details
Age: 50+Biological sex: AllType: InterventionalSponsor: Changhai HospitalUpdated: Nov 17, 2020Locations: 8
Eligibility criteria

Age ≥ 50 years at time of consent. [+7]

Subjects with pulmonary hypertension (systolic pressure ≥ 55mmHg determined by r... [+11]